We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ALXO ALX Oncology Holdings Inc

-0.175 (-2.11%)
Last Updated: 12:05:54
Delayed by 15 minutes


Draw Mode:

Volume 87,939
Bid Price 8.12
Ask Price 8.13
News -
Day High 8.4094


52 Week Range


Day Low 7.98
Share Name Share Symbol Market Stock Type
ALX Oncology Holdings Inc ALXO NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.175 -2.11% 8.125 12:05:54
Open Price Low Price High Price Close Price Previous Close
8.11 7.98 8.4094 8.30
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
1,262 87,939 US$ 8.22 US$ 722,423 - 3.9357 - 12.33
Last Trade Type Quantity Price Currency
12:06:19 3 US$ 8.12 USD

ALX Oncology Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
405.03M 49.82M - 0 -123.48M -2.48 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

ALX Oncology News

Date Time Source News Article
11/13/202315:05GlobeNewswire Inc.ALX Oncology Reports Third Quarter 2023 Financial Results..
11/13/202315:03Edgar (US Regulatory)Form 8-K - Current report
11/01/202315:05GlobeNewswire Inc.ALX Oncology Announces November Investor Conference..
10/10/202315:05GlobeNewswire Inc.ALX Oncology Announces Closing of Public Offering, Including..
10/06/202305:06Edgar (US Regulatory)Form 8-K - Current report
10/06/202305:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]
10/05/202307:00GlobeNewswire Inc.ALX Oncology Announces Pricing of Public Offering
10/04/202316:21Edgar (US Regulatory)Form 8-K - Current report
10/04/202316:21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]
10/04/202315:10GlobeNewswire Inc.ALX Oncology Announces Proposed Public Offering
10/04/202307:00Edgar (US Regulatory)Form 8-K - Current report
10/03/202309:03IH Market NewsKeep An Eye Out: Pre-Market Movers And Recommendations
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ALXO Message Board. Create One! See More Posts on ALXO Message Board See More Message Board Posts

Historical ALXO Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week8.839.307.358.21401,242-0.705-7.98%
1 Month9.1110.497.358.70371,770-0.985-10.81%
3 Months4.8910.494.647.701,363,6863.2466.16%
6 Months8.2510.493.93577.53736,694-0.125-1.52%
1 Year11.3312.333.93577.39491,853-3.21-28.29%
3 Years72.36117.453.935722.98375,035-64.24-88.77%
5 Years30.44117.453.935723.99348,558-22.32-73.31%

ALX Oncology Description

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |